Genetic variation in the CYP2B6 Gene is related to circulating 2,2’,4,4’-tetrabromodiphenyl ether (BDE-47) concentrations: an observational population-based study by Johanna Penell et al.
Penell et al. Environmental Health 2014, 13:34
http://www.ehjournal.net/content/13/1/34RESEARCH Open AccessGenetic variation in the CYP2B6 Gene is related
to circulating 2,2’,4,4’-tetrabromodiphenyl ether
(BDE-47) concentrations: an observational
population-based study
Johanna Penell1, Lars Lind2, Tove Fall3, Anne-Christine Syvänen4, Tomas Axelsson4, Per Lundmark4,
Andrew P Morris5, Cecilia Lindgren5, Anubha Mahajan5, Samira Salihovic6, Bert van Bavel6, Erik Ingelsson3,5
and P Monica Lind1*Abstract
Background: Since human CYP2B6 has been identified as the major CYP enzyme involved in the metabolism of
2,2’,4,4’-tetrabromodiphenyl ether (BDE-47) and that human 2B6 is a highly polymorphic CYP, with known
functional variants, we evaluated if circulating concentrations of a major brominated flame retardant, BDE-47, were
related to genetic variation in the CYP2B6 gene in a population sample.
Methods: In the population-based Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study
(men and women all aged 70), 25 single nucleotide polymorphisms (SNPs) in the CYP2B6 gene were genotyped.
Circulating concentrations of BDE-47 were analyzed by high-resolution gas chromatography coupled to high-resolution
mass spectrometry (HRGC/ HRMS).
Results: Several SNPs in the CYP2B6 gene were associated with circulating concentrations of BDE-47 (P = 10−4 to 10−9).
The investigated SNPs came primarily from two haplotypes, although the correlation between the haplotypes was
rather high. Conditional analyses adjusting for the SNP with the strongest association with the exposure (rs2014141)
did not provide evidence for independent signals.
Conclusion: Circulating concentrations of BDE-47 were related to genetic variation in the CYP2B6 gene in an elderly
population.
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Polybrominated diphenyl ethers (PBDEs) are flame-retardant
chemicals that are commonly used in textiles such as
clothes and furniture, electronic equipment, plastics and
various inflammable materials to prevent fires [1,2]. The
Stockholm Convention in 2009 listed penta- and octa-
PBDE as new persistent organic pollutants and classified
them as materials requiring international regulation [3].
The use of certain PBDEs has been restricted or banned in
the European Union since 2004. However, due to their* Correspondence: Monica.Lind@medsci.uu.se
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unless otherwise stated.persistence in the environment these chemicals have
become ubiquitous environmental pollutants and can
be detected in air, soil and water. Despite the growing
concern there is, in general, little information about the
risks these chemicals pose to public health [4]. Con-
centrations of serum PBDEs has been associated with
self-reported hand-to-mouth behaviors, including biting
nails and licking fingers, and ownership of a large-
screen TV [5]. PBDEs have a neurotoxic potential and
higher concentrations of PBDE have been associated
with various adverse outcomes in children such as im-
paired cognitive and behavior development [6]. Further-
more, associations between PBDEs (BDE 47, 99 and
100) in house dust and hormone levels in men havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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effects reported in relation to PBDE concentrations, it is
of outmost importance to increase the understanding of
PBDE metabolism. 2,2’,4,4’-tetrabromodiphenyl ether
(BDE-47) is the most commonly detected PBDE congener
in human serum worldwide [8-13]. We have previously
reported concentrations of BDE-47 in the majority of
elderly men and women in a population-based sample
[14]. We use this congener as a marker for PBDE exposure
as it is frequently detected and included in a large number
of biomonitoring studies and thus valid for comparison.
Enzymes produced from the cytochrome P450 (CYP)
genes are primarily found in the liver and they are
involved in the synthesis and metabolism of various
molecules and chemicals within cells [15]. Apart from the
role CYP enzymes play in the synthesis of steroid hor-
mones, certain fats, and acids used to digest fats, they are
also involved in metabolizing endogenous toxins and
xenobiotics for example pharmaceuticals and environ-
mental pollutants such as PBDEs [16].
The metabolism of brominated flame retardants has
been extensively studied in the experimental setting. In
human liver microsomes, CYP2B6 plays a key role in the
biotransformation of many xenobiotics [17] and has been
identified as the major CYP enzyme involved in the
metabolism of BDE-47 [18,19]. Furthermore, in rat hepa-
toma cells and in zebrafish embryos, a BDE-47 mixture
enhanced CYP2B gene expression [20]. Also, studies with
recombinant CYPs support CYP2B6 as the major CYP in
CYP-mediated metabolism of BDE-47 [19].
The activity of an enzyme and the gene expression
may be modified by single nucleotide polymorphisms
(SNPs) [17]. The CYP2B6 sequence carries high variance
[21,22] and up to today at least 29 variants have been
described [23]. A majority of the variation in CYP450
activity relates to SNPs in the CYP450 gene locus [21].
Certain SNPs in the region have a large impact on CYP
activity [24] such as altering the composition of transcribed
protein [21] and affect the interindividual differences in
xenobiotic metabolism [25]. Several single nucleotide poly-
morphisms (SNPs) in the P450 system have been reported
to influence the activity of different CYP enzymes that are
important for metabolism of both endogenous, exogenous
and xenobiotic compounds [21,25,26]. For example, a
specific genotype in CYP2B6 has been shown to affect
the xenobiotic metabolism of an anti-HIV agent [27].
Also, effects of certain SNPs have been reported, for
example rs2279345 was found to be associated with a
higher clearance and a lower plasma concentration of
methadone [28]. On the contrary, several SNP polymor-
phisms (including rs8192719) were underrepresented in
the low-methadone group suggesting decreased CYP2B6
activity [29]. When 13 SNPs in CYP2B6 (five of which
are included in this study) were investigated regardingplasma efavirenz (a HIV-medication) concentrations, 3 SNPs
(rs10403955 (not investigated in this study), rs2279345
and rs8192719) were found representative of the 11
SNPs associated with plasma efavirenz concentrations
[30]. There is evidence on species differences in the me-
tabolism of BDE-47 [16]. However, for humans, there is
a lack of knowledge regarding the impact of SNPs in
CYP2B6 on BDE-47 metabolism and plasma concentra-
tions in the real-life setting. Such information may pro-
vide clinically useful information on recommendations
to reduce exposure to BDE-47 in certain susceptible
individuals. This study investigated whether the expe-
rimental findings on the associations between SNPs
in CYP2B6 regarding BDE-47 concentrations could be
repeated in an epidemiological cross-sectional observa-
tional study in humans. We used data from the Pro-
spective Investigation of the Vasculature in Uppsala
Seniors (PIVUS) study to study if SNPs in cytochrome
P450 2B6 (CYP2B6) gene, encoding the only enzyme in
the CYP2B subfamily that is expressed in the liver in
humans, were related to circulating concentrations of
BDE-47 in men and women by applying multivariable
linear regression model techniques.
Methods
Study population
All men and women aged 70 and living in the community
of Uppsala, Sweden at enrolment between April 2001 and
June 2004 were eligible for the study. Two thousand and
twenty five participants were randomly selected from the
national register of residence and invited to the study. A
total of 1016 subjects participated (participation rate
50.1%). The study was approved by the Ethics Committee
of the University of Uppsala (diary number 2007/302) and
all the participants gave their written informed consent.
All subjects were investigated in the morning after an
over-night fast. No medication or smoking was allowed
after midnight. The participants also answered a ques-
tionnaire about their medical history, regular medica-
tion, and smoking and exercise habits. Approximately
10% of the cohort reported a history of coronary heart
disease, 4% reported stroke and 9% reported diabetes
mellitus. Almost half the cohort reported some sort of
cardiovascular medication (45%), with antihypertensive
medication being the most prevalent (32%). Fifteen per-
cent reported use of statins, while oral antiglycemic drugs
and insulin use were reported in 6 and 2%, respectively.
Eleven percent were current smokers, see reference [31]
for details. Blood samples were taken through an arterial
cannula inserted in the brachial artery [31].
BDE-47 analysis
BDE-47 concentrations were measured in stored plasma
samples collected at the baseline investigation using a
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nologies, Atlanta, GA, USA) coupled to a high-resolution
mass spectrometer (Micromass Autospec Ultima,Waters,
Milford, MA, USA) (HRGC/HRMS) based on the method
by Sandau and co-workers [32] with some modifications. A
more detailed description of the analysis in this sample has
previously been presented [33].
In 255 (28%) of the persons included in the analyses,
BDE-47 was below the detection limit (9.2 pg/ml). In
those subjects the value was set to the detection limit
divided by the squared root of two, which is a commonly
used method to impute censored data [34]. This has
been recommended when relatively few data are below
the detection limit or where data are not highly skewed
[35]. Therefore, this procedure has been widely used be-
cause of its simplicity and ease of operation and produce
low bias and moderate precision using environmental
data [36]. Lipid-normalized values (ng/g lipid) for BDE-
47 were used in the analysis. The total amount of lipids
in each plasma sample was obtained by using an estab-
lished summation formula based on serum cholesterol
and serum triglyceride concentrations [37]. In the next
step, using the wet-weight concentration of the BDE-47
as nominator and the amount of lipids as the denomin-
ator, lipid-normalized BDE-47 values were obtained.
Genotyping
A total of 25 SNP in the P450 enzyme CYP2B6 gene
were genotyped using the Illumina OmniExpress chip at
Wellcome Trust Sanger Institute, Oxford, UK (20 SNPs)
and a custom Illumina Golden Gate assay at the SNP&SEQ
Technology Platform at Uppsala University, Uppsala,
Sweden (http://www.genotyping.se) (5 SNPs). Sample
exclusion criteria included: 1) genotype call rate <95%; 2)
heterozygosity >3 standard deviations (SDs); 3) gender
discordance; 4) duplicated samples; and 5) no identity-
by-descent match. SNP exclusion criteria included: 1)
monomorphic SNPs; 2) Hardy-Weinberg equilibrium
(HWE) p-value < 1×10-6 for the GWAS selected SNPs
and P < 0.05 for the directly genotyped SNPs; 3) geno-
type call rate <0.99 for SNPs with minor allele fre-
quency (MAF) <5%, or <0.95 for SNPs with MAF ≥ 5%.
One SNP (rs1272165) failed to meet SNP exclusion cri-
teria 3, and hence was excluded from further analyses.
Using the European 1000 Genomes genotypes as refer-
ence (population codes: CEU, FIN, GBR, IBS, TSI), the
gene region for CYP2B6, length 41.9 kb, contained 128
SNPs with MAF > 5%. The SNPs genotyped in this study
could tag 110 of these at r^2 > 0.8. All SNPs genotyped
in the study were present in the 1000 Genomes data.
Statistics
BDE-47 concentrations were transformed to the natural
logarithm scale prior to analysis to account for the non-normal distribution. Relationships between the CYP2B6
SNPs and BDE-47 concentrations were evaluated by lin-
ear regression analysis with BDE-47 as dependent linear
variable adjusting for gender and the principal compo-
nents 1 and 2 (derived from EIGENSTRAT based on
GWAS data). Each SNP was coded as 0, 1 or 2 alleles of
the minor allele and evaluated in a separate multivariable
model assuming additive allele effect. The p-values were
adjusted to account for multiple testing (see below).
Principal components were included to account for any
possible population stratification in the study popu-
lation that may bias the relationships under study. To
investigate if there were several independent signals, the
analyses were also performed for the remaining SNPs
when adjusting for the lead (i.e. lowest p-value) SNP in
addition to gender and the principal components 1 and
2 (i.e. conditional analysis). To investigate if associations
between BDE-47 and SNP were stable regardless if the
BDE-47 concentrations were above or below the detect-
ible limit, logistic regression analysis with a binary vari-
able for non-detectable/detectable BDE-47 concentra
tions as dependent variables and the SNPs, gender and
the principal components 1 and 2 as independent
variables was performed. Since 24 tests were performed
in the main linear and logistic regression analyses, we ad-
justed the critical p-value accordingly using the Bonferroni
correction (p-value = 0.05/24 = 0.0021 for statistical sig-
nificance). The use of this strict threshold, not taking into
account the high correlations of SNPs within the same LD
blocks which would warrant a more liberal threshold, was
motivated by the lack of suitable replication samples (see
further in the Discussion section).
Results
The number of study subjects included in the analyses
was 924 of which 462 were women (50%). The mean
value for the lipid-normalized BDE-47 was 4.3 (SD 20.1,
range 0.6-476) ng/g lipid. The median value was 2.0
(1.2-3.0 for 25th and 75th percentile) ng/g lipid.
The associations between 24 SNPs in the CYP2B6
gene and circulating concentrations of lipid-normalized
BDE-47 are presented in Table 1. For example, in Table 1
the beta coefficient for rs2014141 versus lipid-normalized
ln-transformed BDE-47 was −0.21. This should be inter-
preted as that the per-allele effect of the SNP will cor-
respond to a 0.21 decrease in lnBDE-47 concentrations
which corresponds to e-0.21 = 19% decrease in total
serum BDE-47 concentrations. Figure 1 shows the asso-
ciation signal plot for SNPs mapping to CYP2B6 with
BDE-47. The haplotype structure of the CYP2B6 SNPs
based on the PIVUS data is shown in Figure 2.
Circulating BDE-47 concentrations were significantly
associated with several of the investigated CYP2B6 vari-
ants, even after taking multiple testing into account. The
Table 1 Association between SNPs in the CYP2B6 gene and circulating lipid-normalized levels of BDE-47
SNPa position Minor allele/
major allele
MAFb nobs in the
analysis
Beta (95% CI) on natural
logaritm scale
P-value (Bonferroni-corrected
p-value for significance = 0.0021)
rs1808682c 41489448 A/G 0.23 920 0.11 (0.026, 0.19) 9.5*10−3
rs3760657 41495433 G/A 0.12 924 0.16 (0.058, 0.27) 2.5*10−3
rs2099361 41498348 C/A 0.36 923 −0.18 (−0.25, −0.11) 2.8*10−7
rs2014141 41499989 A/G 0.41 924 −0.21 (−0.28, −0.14) 4.9*10−9
rs8192711 41500057 A/G 0.05 923 −0.12 (−0.27, 0.031) 0.12
rs8100458 41500213 C/T 0.35 924 0.17 (0.10, 0.24) 3.4*10−6
rs4803415 41500593 T/C 0.10 886 0.19 (0.08, 0.30) 6.9*10−4
rs8101756 41502522 C/T 0.24 923 0.062 (−0.018, 0.14) 0.13
rs16974799 41504077 T/C 0.24 924 0.062 (−0.018, 0.14) 0.13
rs4803417 41508020 C/A 0.41 924 −0.21 (−0.28, −0.14) 4.9*10−9
rs10500282 41508442 C/T 0.26 923 0.087 (0.009, 0.16) 0.028
rs11672911 41508744 A/G 0.32 924 0.17 (0.10, 0.25) 5.6*10−6
rs2279345 41515702 T/C 0.39 924 −0.17 (−0.24, −0.10) 9.6*10−7
rs8192718 41515814 A/G 0.02 924 −0.099 (−0.39, 0.19) 0.50
rs6508965 41517688 T/C 0.39 924 −0.17 (−0.24, −0.10) 1.1*10−6
rs8192719 41518773 T/C 0.24 924 0.066 (−0.012, 0.14) 0.10
rs11882450 41520142 G/A 0.06 924 −0.095 (−0.24, 0.052) 0.20
rs11673270 41520844 C/A 0.24 924 0.060 (−0.019, 0.14) 0.14
rs7260329 41521638 A/G 0.32 924 0.17 (0.093, 0.24) 9. 3*10−6
rs2291287 41522451 G/A 0.06 924 −0.095 (−0.24, 0.052) 0.20
rs1042389c 41524153 G/A 0.21 923 0.040 (−0.041, 0.12) 0.33
rs1552223 41525952 G/A 0.39 924 −0.16 (−0.23, −0.092) 5.0*10−6
rs2113103c 41528667 A/G 0.15 924 0.076 (−0.018, 0.17) 0.11
rs7255904c 41529020 A/G 0.45 921 0.13 (0.059, 0.19) 2.6*10−4
aSNP = single nucleotide polymorphisms.
bMAF = Minor allele frequency.
cSNPs genotyped in Uppsala, others in Oxford.
The position data originates from the UCSC Genome Browser on Human February 2009 (GRCh37/hg19) and allele data originates from the genotyped SNPs
included in the study. All SNPs are located on chromosome 19.
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(Figure 2; all p = 2.6*10−4 to 4.9*10−9). The two top
SNPs rs2014141 and rs4803417 were in complete LD.
The median values for the lipid-normalized BDE-47 for
0, 1 and 2 copies of the minor allele for rs2014141 were
4.3 (1.8-3.7 for 25th and 75th percentile), 4.8 (1.2-2.9 for
25th and 75th percentile) and 3.0 (1.1-2.3 for 25th and
75th percentile) ng/g lipid, respectively. Thirty five per-
cent of the subjects had 0 copies of the minor allele
whereas 17 percent had 2 copies of this allele. In
addition, one SNP with MAF of 0.10 showed significant
association with the outcome (rs4803415, p = 6.9*10−4).
While close relationships were seen between the SNPs
within the two haplotypes as expected, high LD (R2 >
0.90) was also observed between SNPs across the two
haplotypes (Figure 2).
Conditional analyses were performed by adding one of
the top SNPs (i.e. SNPs with lowest p-value from the mainanalyses, see Table 1), rs2014141, to the models of the
other SNPs to investigate independent signals; none of
the other 22 SNPs showed significant association with
the BDE-47 concentrations.
Since 255 subjects showed BDE-47 concentrations
below the limit of detection, we additionally performed
logistic regression analysis with a binary variable for non-
detectable/detectable BDE-47 concentrations as dependent
variables and the SNPs, gender and the principal compo-
nents 1 and 2 as independent variables in separate models
for each SNP. That approach resulted in similar results
as in the linear models described above, with highly
significant associations between low BDE-47 concentra-
tions and the genotypes with MAF in the 0.36-0.45
range (all p = 10-4 to 10−6)(data not shown). Figure 3
shows the relationship between the proportion of non-
detectable concentrations in the sample and genotypes
for one of the top SNPs (rs2014141).
Figure 1 Association signal plot for SNPs mapping to CYP2B6. Each point represents a SNP in the association analysis, plotted with their
p-value (on a -log10 scale) as a function of genomic position (NCBI Build 36). The lead SNP (with maximal association signal) is represented by
the purple symbol. The shape of the plotting symbol corresponds to the annotation of the SNP: square for synonymous or UTR; and circle for
intronic or non-coding. The colour coding of all other SNPs indicates LD with the lead SNP (estimated by CEU r2 from Phase II HapMap): red r2≥ 0.8;
gold 0.6≤ r2 < 0.8; green 0.4≤ r2 < 0.6; cyan 0.2≤ r2 < 0.4; blue r2 < 0.2; grey r2 unknown. Recombination rates are estimated from Phase II HapMap
and gene annotations are taken from the University of California Santa Cruz genome browser.
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The present study, including a homogenous population
of 70-year-old Caucasian men and women showed that
genetic variation in the CYP2B6 gene was related to
circulating concentrations of the brominated flame
retardant BDE-47. This finding is in line with previous
experimental findings that BDE-47 was mainly biotransformed by CYP2B enzyme in human microsomes
and could induce CYP2B enzymes in rats, respectively
[18,20]. It has also been shown that BDE-47 induces
CYP2B6 genes in mice and human hepatocytes, al-
though at higher BDE-47 concentrations than generally
found in humans [38,39]. There is yet no evidence that
BDE-47 can induce CYP genes at the concentrations
Figure 2 Display over the haplotype structure of the CYP2B6-loci, based on PIVUS genotype data. Darker color corresponds to higher








Genotypes for rs2014141 in the CYP2B6 gene
Proportion of subjects with non-detectable BDE47 levels
Figure 3 Proportion of subjects with non-detectable BDE-47 levels according to the rs2014141 genotype in the CYP2B6 gene.
NAA allele = 163, NAG allele = 457, NGG allele = 329.
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BDE-47 can induce CYP2B6 enzymes also at lower
concentration, this will have implications on human
response to numerous therapeutic drugs [39]. There is
also evidence that other xenobiotics may induce or
modulate CYP2B6 in humans. For example the anti-
retroviral drug rilpivirine and a malaria drug were seen
to inhibit CYP2B6 in vitro [40,41] as well as the anti-
platelet drug ticlopidine in vivo [42]. Furthermore,
carnosic acid which has been suggested as a potential
treatment for obesity and nonalcoholic fatty liver dis-
ease has showed increased CYP2B6 enzyme activity
thus indicating a potential drug interaction with carno-
sic acid [43]. In the present study, the strongest associ-
ations were seen between BDE-47 concentrations and
the more common variants, which are also the most
well-powered relationships to find. Additional condi-
tional analysis adjusting for one of the top SNPs did
not provide evidence of multiple signals. This implies
that rs2014141 and rs4803417 might lie closest to the
causal variant. Allelic heterogeneity (i.e. several causal
mutations on different alleles/positions within a locus)
cannot, however, be excluded due to the limited sample
size and hence the low power to detect low frequency sig-
nals. Since we are not aware of any other population-
based study with BDE measurements in a fairly large
cohort in which also genetic analysis in CYP genes has
been performed, we cannot replicate the findings in an
independent cohort. Hence, we acknowledge the lack of
replication as an important limitation, but believe that
the study still is valuable due the high a priori probabil-
ity for involvement of CYPs in the metabolism of bro-
minated flame retardants. Also, the p-values well below
the Bonferroni corrected p-values for statistical signifi-
cance support the likelihood of the results not being
chance findings.
Previously many studies have addressed the effect of
variability in CYP2B6 on various xenobiotics [22,25,28,44].
Some of these studies include specific SNPs also investi-
gated in this study. For example rs2279345 was associated
with lower concentrations of methadone [28] and efavir-
enz plasma concentration [45] which is the same direction
of the highly significant effect that is reported in this study
for the intron variant rs2279345 on BDE-47 concentra-
tions. Also rs8192719 has been reported to be related
to methadone although in the opposite direction by
lower CYP2B6 activity [29]. We did not see any associ-
ation between this SNP and BDE-47 concentrations.
Also rs1042389 has been investigated and found not be
associated with response to two treatments of HIV in-
fection [46] which mimics the no-existing relationship
between this SNP and BDE-47 concentrations seen in
this study. In addition, we compared the two top SNPs
rs2014141 and rs4803417 identified in this study withpreviously known variants using HapMap release 22 and
population panel CEU (http://www.broadinstitute.org/mpg/
snap/ldsearch.php). This revealed that rs2014141 has
perfect LD with rs6508964 and rs10418990 (r2 = 1.00), and
high LD with rs2099361 and rs3889806 (both r2 = 0.87).
For rs4803417, the correlation pattern was similar with
high LD with SNPs rs6508964 and rs10418990 (r2 = 0.93),
and with rs2099361 and rs3889806 (both r2 = 0.81). The so
far most commonly studied CYP2B6 SNP rs3745274 [30],
which is a missense variant, where polymorphism is associ-
ated with for example lower hepatic expression and enzym-
atic activity for CYP2B6 [47], higher efavirenz exposure
[48], plasma propofol concentrations [49] and increased
breast cancer risk [50] was in low LD with the two top
SNPs in this study (r2 = 0.29). Similarly, two other well-
studied missense variants SNPs rs3211371 and rs2279343
associated with altered metabolism of various substrates
[51] was also in low LD with the two top SNPs in this study
(r2 = 0.29). Many other CYP2B6 SNPs have been reported
to be associated with various phenotypes, however, none
were in high LD with our two top SNPs. For example, nei-
ther SNPs related to nicotine metabolism (rs8109525, r2 =
0.28) [51] or to altered expression of the CYP2B6 enzymes
(e.g. the missense variants rs8192709 and rs3211371, r2 <
0.2 ) [22], nor marker SNPs for plasma efavirenz concentra-
tions (rs10403955 and rs8192719, r2 = 0.34 and 0.31,
respectively ) [30] were in LD (r2 < 0.2) with rs2014141 and
rs4803417.
The clinical implications of genotype polymorphism
affecting BDE-47 concentrations are yet to be fully
understood. We interpreted the findings in this study so
that genotype may be a predictor of BDE-47 metabolism
by affecting the BDE-47 concentrations. The suggested
causal pathway from genotype to BDE-47 concentrations
implies that genetic variability in the CYP2B6 gene may
lead to interindividual variability in the concentrations of
BDE-47. This could have clinical relevance in subgroups
with genotypes associated with higher PBDE concentra-
tions or for individuals where PBDE concentrations should
be kept to a minimum. For example, this would be of
interest to pregnant women and parents bearing in mind
the neurotoxicological, behavior and hormone disruptive
effects that have been reported to be associated with
PBDE exposure [6,7]. Taking advantage of genotyping has
previously been suggested for example regarding selecting
anaesthetics for optimal anesthesia that reduce risk of side
effects as well as undesirable actions [52]. Analogously, as
SNPs have been shown to affect the pharmacokinetics and
response to a HIV-treatment drug [44] we suggest that
detailed knowledge on SNP may be clinically relevant also
regarding PBDE concentrations and metabolism.
Cytochrome P450 enzymes account for the majority of
enzymes involved in drug metabolism. Common varia-
tions (polymorphisms) in cytochrome P450 genes can
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medications. Indeed, several single nucleotide polymor-
phisms (SNPs) in the P450 system have been discovered
to influence the activity of different CYP enzymes. Fur-
thermore, a recent review on variations of cytochrome
P450 in different ethnic populations suggests that ethni-
cal differences in metabolic phenotype can be explained
by differences in the distributions of SNPs [21]. Import-
ant substrates for CYP2B6 include nicotine and the anti-
depressant and smoking cessation aid bupropion [53,54].
As both BDE-47 concentrations [4] and ethnic compos-
ition of the population varies across the world, assess-
ment of the effect of BDE-47 on CYP2B6 on a wide
range of exposure concentrations and different popula-
tions is relevant even though significant variation of
CYP isoform activity may also occur within subgroups of
a specific ethnic group [21]. In addition to being abundant
in the liver, CYP2B6 is present in most regions of the brain
[55]. This could be the reason why PBDE exposure has
been associated with neurotoxicity and neurological dis-
eases and could also reflect variability between individuals
in response to centrally acting drugs.
The two haplotypes seen in this study agrees somewhat
with earlier findings in that rs8100458 and rs2279345 were
located in different haplotypes [28].
Ideally, the role of CYP induction on the metabolism
of a xenobiotic, such as BDE-47, should be studied by
distributing a fixed dose of the compound at a certain
time point and thereafter evaluate the concentrations of
the compounds in a standardized fashion. This is obvi-
ously not the case in the present observational epidemi-
ologic study where there is no information on amount
and timing of the BDE-47 exposure. However, by study-
ing this relationship in an epidemiologic study including
men and women, we may observe a relationship that
more corresponds to real life settings. Furthermore, by
including persons of the same age at a certain rather
small time interval, we reduce variability due to age and
time differences in exposure. Indeed, the major strength
of the study is the rather large number of subjects with
measurements of BDE-47 at the same age, which would
increase the likelihood of establishing true relationships. A
limitation of this study is that approximately one fourth
of the sample had circulating concentrations of BDE-47
below the detection level. However, the additional analysis
comparing observations with non-detectable and de-
tectable concentrations of BDE-47 yielded similar re-
sults as the main findings indicating robustness of the
study findings.
Future research on effects of BDE-47 exposure on
humans may include proteome changes or differential
protein expressions to determine if the molecular
machinery could be adjusted to cope with e.g. BDE-47
exposure.Conclusions
Circulating concentrations of BDE-47 were related to
genetic variation in the CYP2B6 gene in an elderly popu-
lation. Future research may investigate the protein ex-
pression pattern related to BDE exposure and determine
if genetic adaptation to improve the resistance to BDE
may occur in human populations as a response to this
exposure.
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